Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Rhea-AI Summary

Tango Therapeutics (NASDAQ: TNGX) announced the selection of three abstracts for poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, scheduled from October 26-28, 2022. The posters will cover the characterization and potential of TNG908 and TNG462, both designed to target MTAP-deleted cancers. Notably, TNG908 is highlighted as a brain-penetrant inhibitor, while TNG462 aims to be a best-in-class option. These presentations showcase Tango's focus on precision cancer therapies.

Positive

• Three abstracts selected for presentation at a notable symposium, showcasing research credibility.
• TNG908 characterized as a novel MTA-cooperative PRMT5 inhibitor, indicating innovative development.
• TNG462 identified as a potential best-in-class inhibitor, highlighting promising pipeline advancements.

Negative

• Tango has not generated revenue from drug sales to date, indicating ongoing financial challenges.
• Limited experience in conducting clinical trials, raising concerns about operational execution.
• Potential delays in clinical trials due to reliance on third-party operations.

BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that three abstracts have been selected for presentation as posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held in Barcelona, Spain from October 26-28, 2022.

Details on the Tango presentations at the EORTC-NCI-AACR Symposium are as follows:

Poster Title: Biochemical characterization of TNG908 as a novel, potent MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancers
Abstract #: 75
Date and Time: Wednesday, October 26, 12:00 PM CEST

Poster Title: TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancer
Abstract #: 233
Date and Time: Thursday, October 27, 10:00 AM CEST

Poster Title: TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of peripheral MTAP-deleted solid tumors
Abstract #: 234
Date and Time: Thursday, October 27, 10:00 AM CEST

About Tango Therapeutics

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.

Forward-Looking Statements

Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future operating performance and goals, the anticipated benefits of therapies and combination therapies (that include a Tango pipeline product), expectations, beliefs and development objectives for Tango’s product pipeline and clinical trials. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. For example, statements concerning the following include or constitute forward-looking statements: the expected benefits of TNG908 and the Company's other development candidates and other product candidates (as a standalone therapy of in combination with other therapies); TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of peripheral MTAP-deleted solid tumors; and the expected timing of: (i) development candidate declaration for certain targets; (ii) initiating IND-enabling studies; (iii) filing INDs; (iv) clinical trial initiation; and (v) disclosing initial and final clinical trial results. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: Tango has limited experience conducting clinical trials (and will rely on a third party to operate the clinical trial for TNG908) and may not be able to commence the clinical trial (including opening clinical trial sites and enrolling and dosing an adequate number of clinical trial participants) when expected and may not generate results (including final or initial safety and efficacy data) in the anticipated timeframe (or at all); benefits of product candidates seen in preclinical analyses may not be evident when tested in clinical trials or when used in broader patient populations (if approved for commercial sale); the benefits of Tango pipeline products, development candidates and potential combination therapies that are seen in pre-clinical experiments may not be present in clinical trials or in use commercially or may not be safe and/or effective in humans; Tango has a limited operating history and has not generated any revenue to date from drug sales, and may never become profitable; the Company may not be able to file INDs for development candidates on time, or at all, due to technical or financial reasons or otherwise; Tango will need to raise capital in the future and if we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our development programs or future commercialization efforts; we may be unable to advance our preclinical development programs into and through the clinic for safety or efficacy reasons or commercialize our product candidates or we may experience significant delays in doing so as a result of factors beyond Tango’s control; Tango’s approach to the discovery and development of product candidates is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products; our products candidates may cause adverse or other undesirable side effects (or may not show requisite efficacy) that could, among other things, delay or prevent regulatory approval; our ability to obtain and maintain patent and other intellectual property protection for our technology and product candidates or the scope of intellectual property protection obtained is not sufficiently broad; and delays and other impacts on product development and clinical trials from the COVID-19 pandemic. Additional information concerning risks, uncertainties and assumptions can be found in Tango’s filings with the SEC, including the risk factors referenced in Tango’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as supplemented and/or modified by its most recent Quarterly Report on Form 10-Q. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.

Investor Contact:

Sam Martin/Andrew Vulis
Argot Partners
tango@argotpartners.com

Media Contact:

Joshua R. Mansbach
Argot Partners
tango@argotpartners.com

FAQ

What is the purpose of TNG908 in cancer treatment?

TNG908 is designed as a novel, potent MTA-cooperative PRMT5 inhibitor for treating MTAP-deleted cancers.

When will Tango Therapeutics present their research at the EORTC-NCI-AACR Symposium?

Tango will present their findings from October 26-28, 2022, in Barcelona.

What are the key highlights of TNG462?

TNG462 is positioned as a potential best-in-class MTA-cooperative PRMT5 inhibitor targeting peripheral MTAP-deleted solid tumors.

Is Tango Therapeutics currently generating revenue?

No, Tango Therapeutics has not generated any revenue from drug sales to date.

What are the risks associated with Tango's clinical trials?

Tango faces risks due to limited clinical trial experience and reliance on third-party operations, which may lead to delays.